Pharmacoeconomics: friend or foe?

M. Drummond

doi:10.1136/ard.2006.058602

Pharmacoeconomics: friend or foe?

M. Drummond

Centre for Health Economics

Research output: Contribution to journal › Article › peer-review

Abstract

The financial constraints faced by most health systems today make it necessary for manufacturers of new, expensive drugs to demonstrate value for money. This paper describes the different types of economic evaluation; the increasing use of these analysis in decision making; their application to new drugs in the field of in rheumatoid arthritis; and the pros and cons of pharmacoeconomics studies from the perspective of the patients, the physicians, and the general population.

Original language	English
Pages (from-to)	44-47
Number of pages	4
Journal	Annals of the Rheumatic Diseases
Volume	65
DOIs	https://doi.org/10.1136/ard.2006.058602
Publication status	Published - Nov 2006

Bibliographical note

© The Authors, 2006. This is an author-produced version of the published paper. Uploaded in accordance with the publisher’s self-archiving policy. Further copying may not be permitted; contact the publisher for details

Keywords

COST-EFFECTIVENESS
RHEUMATOID-ARTHRITIS
INFLIXIMAB REMICADE(R)
CLINICAL EXCELLENCE
NATIONAL INSTITUTE
DECISIONS
SWEDEN

Access to Document

10.1136/ard.2006.058602

Pharmaco friend foe ARD 2006
© The Authors, 2006. This is an author-produced version of the published paper. Uploaded in accordance with the publisher’s self-archiving policy. Further copying may not be permitted; contact the publisher for details (no embargo)

Cite this

@article{bf9eb84893774c3d9a9821664c0eab2f,

title = "Pharmacoeconomics: friend or foe?",

abstract = "The financial constraints faced by most health systems today make it necessary for manufacturers of new, expensive drugs to demonstrate value for money. This paper describes the different types of economic evaluation; the increasing use of these analysis in decision making; their application to new drugs in the field of in rheumatoid arthritis; and the pros and cons of pharmacoeconomics studies from the perspective of the patients, the physicians, and the general population.",

keywords = "COST-EFFECTIVENESS, RHEUMATOID-ARTHRITIS, INFLIXIMAB REMICADE(R), CLINICAL EXCELLENCE, NATIONAL INSTITUTE, DECISIONS, SWEDEN",

author = "M. Drummond",

note = "{\textcopyright} The Authors, 2006. This is an author-produced version of the published paper. Uploaded in accordance with the publisher{\textquoteright}s self-archiving policy. Further copying may not be permitted; contact the publisher for details",

year = "2006",

month = nov,

doi = "10.1136/ard.2006.058602",

language = "English",

volume = "65",

pages = "44--47",

journal = "Annals of the Rheumatic Diseases",

issn = "0003-4967",

publisher = "BMJ",

}

TY - JOUR

T1 - Pharmacoeconomics

T2 - friend or foe?

AU - Drummond, M.

N1 - © The Authors, 2006. This is an author-produced version of the published paper. Uploaded in accordance with the publisher’s self-archiving policy. Further copying may not be permitted; contact the publisher for details

PY - 2006/11

Y1 - 2006/11

N2 - The financial constraints faced by most health systems today make it necessary for manufacturers of new, expensive drugs to demonstrate value for money. This paper describes the different types of economic evaluation; the increasing use of these analysis in decision making; their application to new drugs in the field of in rheumatoid arthritis; and the pros and cons of pharmacoeconomics studies from the perspective of the patients, the physicians, and the general population.

AB - The financial constraints faced by most health systems today make it necessary for manufacturers of new, expensive drugs to demonstrate value for money. This paper describes the different types of economic evaluation; the increasing use of these analysis in decision making; their application to new drugs in the field of in rheumatoid arthritis; and the pros and cons of pharmacoeconomics studies from the perspective of the patients, the physicians, and the general population.

KW - COST-EFFECTIVENESS

KW - RHEUMATOID-ARTHRITIS

KW - INFLIXIMAB REMICADE(R)

KW - CLINICAL EXCELLENCE

KW - NATIONAL INSTITUTE

KW - DECISIONS

KW - SWEDEN

U2 - 10.1136/ard.2006.058602

DO - 10.1136/ard.2006.058602

M3 - Article

SN - 0003-4967

VL - 65

SP - 44

EP - 47

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

ER -